JP Morgan Chase
ADAP

JP Morgan Chase’s Adaptimmune Therapeutics ADAP Stock Holding History

JP Morgan Chase’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-200,000
Closed -$2M – 5444
2020
Q2 		$2M Buy
+200,000
New +$1.26M ﹤0.01% 3104

Other funds holding ADAP

LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

JP Morgan Chase's ADAP Position: Q3 2025 in Review

JP Morgan Chase sold out of Adaptimmune Therapeutics (ADAP) in Q3 2025, closing a stake of 22,782 shares — an estimated $5.46K sold.

JP Morgan Chase first reported a position in ADAP in Q3 2016 and held it in 36 quarters. The position peaked at $8.95M in Q1 2021. 55 funds tracked by Wall St. Rank hold ADAP as of Q3 2025.

  • JP Morgan Chase reported no remaining Adaptimmune Therapeutics position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 22,782 Adaptimmune Therapeutics shares in Q3 2025, an estimated $5.46K.
  • JP Morgan Chase first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 36 quarters.
  • JP Morgan Chase's Adaptimmune Therapeutics position peaked at $8.95M in Q1 2021.
  • 55 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.